Review
Biology
Paola Cruz-Tapias, Wilson Rubiano, Milena Rondon-Lagos, Victoria-E Villegas, Nelson Rangel
Summary: Studies have shown that high levels of AR mRNA may serve as a promising non-invasive prognostic biomarker, aiding in the identification of less aggressive BC subtypes.
Article
Oncology
Angeleke Saridakis, Elizabeth R. Berger, Malini Harigopal, Tristen Park, Nina Horowitz, Justin Le Blanc, Gregory Zanieski, Anees Chagpar, Rachel Greenup, Mehra Golshan, Donald R. Lannin
Summary: Invasive apocrine carcinomas have more aggressive features than non-apocrine carcinomas but the breast cancer-specific survival is the same. Half of these apocrine tumors are triple negative but these have more favorable features and much better survival than non-apocrine triple-negative cancers. The characteristics of apocrine carcinomas vary dramatically by molecular type, with triple-negative apocrine patients having better survival outcomes compared to non-apocrine triple-negative patients, while luminal apocrine patients have worse survival outcomes compared to non-apocrine luminal patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Surgery
A. Fancellu, N. Houssami, V Sanna, A. Porcu, C. Ninniri, M. L. Marinovich
Summary: This meta-analysis compared the outcomes of breast-conserving surgery (BCS) versus mastectomy in patients with triple-negative breast cancer (TNBC). The results showed that BCS was associated with lower rates of locoregional recurrence, distant metastasis, and all-cause mortality compared to mastectomy. However, caution should be taken due to potential differences in patient selection for the two surgical options.
BRITISH JOURNAL OF SURGERY
(2021)
Review
Oncology
Ebony Hargrove-Wiley, Barbara Fingleton
Summary: Sex hormones such as estrogens and androgens play a crucial role in the pathophysiology of various cancers by regulating genomic and cellular processes. They can modulate immune signals and activities in tumor cells and leukocytes, affecting cancer progression. Understanding the impact of sex hormones on tumor immunity in the breast cancer microenvironment is important for developing effective therapies. Combining endocrine therapy with immunotherapy can enhance the antitumor immune response.
Article
Oncology
Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Summary: AMG 160, a bispecific T-cell engager immuno-oncology therapy targeting PSMA in mCRPC, demonstrates potent antitumor activity in vitro and in vivo. It shows enhanced cytotoxic activity when combined with diagnostic or therapeutic agents such as the PSMA-imaging agent, novel hormonal therapy, and immune checkpoint blockade. Preclinical data supports ongoing clinical evaluation in patients with mCRPC.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jasna Metovic, Fulvio Borella, Marta D'Alonzo, Nicoletta Biglia, Luca Mangherini, Cristian Tampieri, Luca Bertero, Paola Cassoni, Isabella Castellano
Summary: This review article summarizes the roles of the forkhead box A1 protein (FOXA1) in normal and neoplastic tissues, with a focus on its prognostic and predictive role in breast cancer. FOXA1, as a pioneer factor and interacting partner of estrogen and androgen receptors, plays a crucial role in breast cancer development and progression. Its expression has been found to have a significant impact on prognosis and treatment response in breast cancer, making it a potential prognostic and predictive marker. Immunohistochemistry can be used to detect FOXA1 expression and it could be considered for routine diagnostics in breast cancer.
Article
Oncology
Yan Wang, Lili Du, Jiexian Jing, Xianwen Zhao, Xing Wang, Shenghuai Hou
Summary: Effective screening and treatment have reduced the number of women dying from breast cancer, but the long-term effects of treatment and psychosocial factors still affect the quality of life of patients. Therefore, the discovery and application of targeted biomarkers to improve functional outcome and life quality is necessary for breast cancer patients.
Article
Oncology
Emanuele Perrone, Riccardo Tudisco, Pia Clara Pafundi, Davide Guido, Alessandra Ciucci, Enrica Martinelli, Gian Franco Zannoni, Alessia Piermattei, Saveria Spadola, Giulia Ferrante, Claudia Marchetti, Giovanni Scambia, Anna Fagotti, Daniela Gallo
Summary: This study explored the relationship between hormone receptor status and BRCA1/2 mutation in high-grade serous ovarian carcinoma (HGSOC) patients. The results showed interesting differences in receptor expression patterns and their association with outcomes between BRCA-mutated and BRCA wild-type women. The findings suggest a potential role of estrogen-mediated pathways in BRCA1/2-associated HGSOC tumorigenesis, revealing a possible therapeutic potential for targeting this interaction.
Article
Medicine, General & Internal
Gerhardt Attard, Laura Murphy, Noel W. Clarke, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L. Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J. Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S. de Bono, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James
Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.
Review
Oncology
Masa Brumec, Monika Sobocan, Iztok Takac, Darja Arko
Summary: Triple-negative breast cancer lacks hormone receptors and HER2 amplifications, posing challenges in treatment selection. However, some TNBCs express androgen receptor (AR) which can be a therapeutic target. This review summarizes clinical features and potential therapies for AR-positive TNBC and highlights the need for further research on AR signaling pathways.
Review
Surgery
M. G. Davey, E. J. Ryan, M. S. Davey, A. J. Lowery, N. Miller, M. J. Kerin
Summary: Studies have found that high PD-L1 expression in breast cancer is associated with aggressive clinical and pathological characteristics, and is more likely to achieve pathological complete response following treatment, but is also associated with lower overall survival rates.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Oncology
Yara Rodriguez, Kenji Unno, Mihai I. Truica, Zachary R. Chalmers, Young A. Yoo, Rajita Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Maha Hussain, Huiying Han, Sarki A. Abdulkadir
Summary: This study identifies PRRX2 as a driver of enzalutamide resistance in prostate cancer. PRRX2 expression is highest in double-negative prostate cancer cases and its associated gene signature can serve as a biomarker for enzalutamide resistance, which can be reversed with CDK4/6 and BCL2 inhibitors.
Review
Oncology
Matteo Lambertini, Eva Blondeaux, Marco Bruzzone, Marta Perachino, Richard A. Anderson, Evandro de Azambuja, Philip D. Poorvu, Hee Jeong Kim, Cynthia Villarreal-Garza, Barbara Pistilli, Ines Vaz-Luis, Cristina Saura, Kathryn J. Ruddy, Maria Alice Franzoi, Chiara Sertoli, Marcello Ceppi, Hatem A. Azim, Frederic Amant, Isabelle Demeestere, Lucia Del Mastro, Ann H. Partridge, Olivia Pagani, Fedro A. Peccatori
Summary: This study found that breast cancer survivors are less likely to have a subsequent pregnancy compared to the general population, and they face higher risks during pregnancy, especially among those who have received chemotherapy. However, compared to breast cancer patients without subsequent pregnancy, those who become pregnant have better disease-free survival and overall survival rates.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Man Yang, Jiale Sun, Liqiong Liu, Xiangyi Kong, Dongcai Lin, Hong Zhou, Jidong Gao
Summary: This study aimed to explore the differences in clinicopathological indicators and survival outcomes between HER2-low and HER2-0 breast cancers. Retrospectively analyzing 501 invasive breast cancer patients, it was found that HER2-low breast cancer was significantly higher in HR positive breast cancers, and significant differences were observed in lymph node ratio, hormone receptor expression, Ki-67 expression, androgen receptor expression, and adjuvant chemotherapy between HER2-low BCs and HER2-0 BCs. No statistical differences were detected between the two groups for DFS and DDFS.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Huyen Thi Phung, Chu Van Nguyen, Nhung Thi Mai, Ha Thi Ngoc Vu, Khoa Hong Pham, Giang Le Tran
Summary: This study aimed to investigate the expression of androgen receptor (AR) and AR:ER ratio in different subclasses of invasive breast cancer (BC), and explore their correlation with clinicopathological features, prognosis, and survival outcomes. The results showed that positive AR expression and AR:ER<2 ratio were significantly associated with better prognostic features. AR:ER<2 was associated with prolonged overall survival (OS) and disease-free survival (DFS) compared to AR:ER >= 2. However, in hormone receptor-positive (HR + ve) BC, AR expression was not significantly correlated with survival. The multivariate analysis revealed that the ratio of nuclear AR to ER remained as an independent prognostic variable.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
